Revolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) insider Stephen Kelsey sold 27,160 shares of the business's stock in a transaction dated Monday, November 16th. The shares were sold at an average price of $167.86, for a total transaction of $4,559,077.60. Following the completion of the transaction, the insider owned 286,307 shares in the company, valued at approximately $48,059,493.02. The trade was a 8.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Stephen Michael Kelsey also recently made the following trade(s):
- On Wednesday, September 16th, Stephen Kelsey sold 5,569 shares of Revolution Medicines stock. The stock was sold at an average price of $199.24, for a total transaction of $1,109,567.56.
- On Friday, September 11th, Stephen Kelsey sold 92,531 shares of Revolution Medicines stock. The stock was sold at an average price of $202.36, for a total transaction of $18,724,573.16.
Revolution Medicines Stock Performance
Shares of NASDAQ:RVMD traded down $2.87 during mid-day trading on Wednesday, reaching $159.82. The company had a trading volume of 2,339,794 shares, compared to its average volume of 2,810,418. The company has a current ratio of 8.36, a quick ratio of 8.34 and a debt-to-equity ratio of 0.44. The firm has a market cap of $34.57 billion, a price-to-earnings ratio of -17.54 and a beta of 1.44. The company's 50-day moving average price is $192.71 and its 200-day moving average price is $160.09. Revolution Medicines, Inc. has a one year low of $69.50 and a one year high of $224.31.
Revolution Medicines (NASDAQ:RVMD - Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The company reported ($1.90) earnings per share for the quarter, beating the consensus estimate of ($2.35) by $0.45. The firm had revenue of $197.56 million for the quarter, compared to the consensus estimate of $25.58 million. During the same period last year, the company posted ($1.61) earnings per share. As a group, equities research analysts anticipate that Revolution Medicines, Inc. will post -7.41 EPS for the current fiscal year.
Wall Street Analyst Weigh In
RVMD has been the subject of several research reports. Oppenheimer increased their price target on Revolution Medicines from $230.00 to $260.00 and gave the stock an "outperform" rating in a research note on Thursday, August 27th. Guggenheim boosted their price objective on Revolution Medicines from $275.00 to $298.00 and gave the company a "buy" rating in a research note on Thursday, November 5th. Needham & Company LLC restated a "buy" rating and issued a $275.00 price objective on shares of Revolution Medicines in a research note on Thursday, October 15th. Royal Bank Of Canada upped their price objective on shares of Revolution Medicines from $260.00 to $321.00 and gave the company an "outperform" rating in a report on Thursday, November 5th. Finally, HC Wainwright reiterated a "buy" rating and set a $350.00 target price on shares of Revolution Medicines in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $262.75.
View Our Latest Research Report on Revolution Medicines
Institutional Investors Weigh In On Revolution Medicines
Hedge funds and other institutional investors have recently bought and sold shares of the business. Alphabet Inc. bought a new position in shares of Revolution Medicines in the second quarter worth approximately $551,843,000. Assenagon Asset Management S.A. increased its stake in shares of Revolution Medicines by 987.9% in the third quarter. Assenagon Asset Management S.A. now owns 2,181,185 shares of the company's stock worth $447,710,000 after buying an additional 1,980,699 shares during the period. ABS Investment Management LLC bought a new stake in Revolution Medicines during the 2nd quarter valued at $337,104,000. Winslow Capital Management LLC bought a new stake in Revolution Medicines during the 3rd quarter valued at $260,191,000. Finally, Bank of America Corp DE bought a new stake in Revolution Medicines during the 2nd quarter valued at $184,267,000. Institutional investors own 94.34% of the company's stock.
Revolution Medicines Company Profile
(
Get Free Report)
Revolution Medicines, Inc. is a biotechnology company focused on developing targeted therapies for patients with RAS-driven cancers. Founded in 2014 and headquartered in Redwood City, California, the company's research centers on RAS proteins, which can contribute to the growth of many cancers. The company's pipeline includes drug candidates designed to inhibit mutant RAS proteins, including daraxonrasib (RMC-6236), which targets multiple RAS variants, and candidates directed at specific KRAS mutations.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Revolution Medicines, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Revolution Medicines wasn't on the list.
While Revolution Medicines currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.